Translocation of Iris Pigment Epithelium in Patients with Exudative Age-related Macular Degeneration: Long-term Results
Overview
Authors
Affiliations
Purpose: To report the practicability and efficacy of autologous iris pigment epithelium (IPE) translocation in exudative age-related macular degeneration (ARMD) over 1 year.
Methods: The consecutive interventional case series included 56 patients with exudative ARMD. During vitrectomy the submacular neovascular membrane (CNV) was removed and IPE cells, harvested from a peripheral iridectomy, were injected into the submacular space. Included were patients with subfoveal occult CNV (11 eyes), classic CNV (10 eyes), mixed CNV (17 eyes), CNV with a pigment epithelial detachment (13 eyes) or CNV with a hemorrhage (5 eyes). Outcome measures were visual acuity, foveal fixation, size of CNV and rate of recurrence based on fluorescence angiographic imaging.
Results: All patients underwent successful surgical removal of the CNV with consecutive subretinal IPE injection. Visual acuity was better than 20/100 in 19 patients preoperatively and in 18 patients postoperatively. A visual acuity of 20/100 or less was found in 37 patients preoperatively and in 38 patients postoperatively. Mean preoperative visual acuity (1.0+/-0.3 logMAR units) did not change significantly after 1 year (1.0+/-0.3 logMAR units). Ten eyes (18%) developed a recurrence. Fixation within the surgically denuded area could be demonstrated in 25 eyes (45%).
Conclusions: Autologous IPE translocation for ARMD over one year can preserve foveal function on a low level, but cannot improve visual acuity. IPE translocation is technically feasible with a low rate of complications. Continued research seems justified to improve functional outcome.
Deng Y, Qiao L, Du M, Qu C, Wan L, Li J Genes Dis. 2022; 9(1):62-79.
PMID: 35005108 PMC: 8720701. DOI: 10.1016/j.gendis.2021.02.009.
Wang J, Rattner A, Nathans J Elife. 2021; 10.
PMID: 34783308 PMC: 8594943. DOI: 10.7554/eLife.73477.
Thumann G, Harmening N, Prat-Souteyrand C, Marie C, Pastor M, Sebe A Mol Ther Nucleic Acids. 2017; 6:302-314.
PMID: 28325297 PMC: 5363513. DOI: 10.1016/j.omtn.2017.02.002.
Ocular stem cells: a status update!.
Dhamodaran K, Subramani M, Ponnalagu M, Shetty R, Das D Stem Cell Res Ther. 2014; 5(2):56.
PMID: 25158127 PMC: 4055087. DOI: 10.1186/scrt445.
Prospectives for gene therapy of retinal degenerations.
Thumann G Curr Genomics. 2013; 13(5):350-62.
PMID: 23372421 PMC: 3401892. DOI: 10.2174/138920212801619214.